While ARS methodology does not require consensus to be classified as “agreement,” notable areas of consensus, where all votes fell into a single rating category, occurred in treatment scenarios covered by existing ARS-AUC Guidelines for SRS for multiple brain metastases, independent of TKI availability.27 For treatment of newly diagnosed EFGRm or ALK + NSCLC with multiple asymptomatic BrM, SRS to all BrM followed by TKI was usually appropriate for patients with 2–4 BrMs (CV1a). Here, ALK is linked to non-small cell lung carcinoma.